U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE FORM PTO-1449 FEB 1 7 2004

Sheet __1_ of _ 1_

ATTY. DOCKET: 17500 (BOT)

APPLICANT: STEPHEN DONOVAN

FILING DATE: May 10, 2002

LIST OF ACT CITED BY APPLICANT

SERIAL NO.: 10/143,078

TITLE: THERAPEUTIC TREATMENTS FOR NEUROPSYCHIATRIC DISORDERS

GROUP: 1645

U.S. PATENT DOCUMENTS

'EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (If applicable)
	AA						(ii appirousis)
	AB					(m)	
	AC						
	AD						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/n)
BA						()0211
88	·					
BC BC						

OTHER ART
(Including Author, Title, Date, Pertinent Pages, etc.)

VSK I	A.	Bolay, H., et al., "Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model" <i>Nature Medicine</i> , Vol 8, No. 2, February 2002, pp 136-142
, ,	B	7
C	C C	
C	Ö	
C	Æ	
C	F	
C	Œ	
C	ਸ	
C	;	
C	i i	
C	K	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line phrough citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SPAL TOG

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
PORTA PROPERTY

Sheet 1 of 1

ATTY. DOC	KET:	17500 (BOT)		SERIAL NO.: 10	0/143,078			
APPLICANT	?:	STEPHEN DONOV	TO TE VE	TITLE: THER NEUROPSYCHI	TITLE: THERAPEUTIC TREATMENTS FOR RECEIVEUROPSYCHIATRIC DISORDERS			
FILING DAT	TE:	May 10, 2002	SP 0 3 7000	GROUP: 1645			SEP 1.0	
			U.S. PATE	NT DOCUMENTS		T	ECH CENTER 1	
EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)	
	AA						,	
	AB						·	
	AC						· · · · · · · · · · · · · · · · · · ·	
<u> </u>	AD							
			FOREIGN PA	TENT DOCUMENTS				
		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)	
28	ВА	DE10150415A1	5 2003	Germany			Yes First and last	
V	BB						page	
	BC							
		(Includi	OTI ng Author, Title,	IER ART Date, Pertinent Pag	es, etc.)			
(4)	CA	dementia disorde	ers; Eur J Dru	hemistry of musca og Metab Pharma	cokinet 199	94+(3)+ 170-1:	83	
U	CB	Duggan, Michael cells; <i>Moving Dis</i>	J. et al., A su	urvey of botulinum	n neurotoxii	n substrate e	xpression in	
	CC	Sramka, M., et al	Long-term	results in patients <i>Bratisl. Lek. List</i> y	with stere	otaxic surger	y for	
	CD			Dianon Con Listy	, 30, 1332.	7, pgs. 364-3	000	
	CE							
	CF							
	CG					· · · · · · · · · · · · · · · · · · ·		
	СН							
	Cí							
	ದ							
	ck .			_				

BEST AVAILABLE COPY

EXAMINER SPACE OF THE PROPERTY	DATE CONSIDERED 3/2004 is in conformance with MPEP 609; Draw line through citation/if not in
conformance and not considered. Include copy of this form with next co	The state of the s
ment con and the ment con ment con ment con ment con	mmunication to applicant.
$\langle h \rangle \rangle = -$	1

DEPARTMEN	IT OF COMMERCE ADEMARK OFFICE
ATENT AND TR	ADEMARK OFFICE
OPM PTYLIAAO	

Sheet __1__ of __1_

	LIST OF ART CITED BY APPLICANT						
ATTY. DOCKET:	17500 (BOT)	SERIAL NO.: 10/143,078					
APPLICANT:	STEPHEN DONOVAN	TITLE: THERAPEUTIC TREATMENTS FOR NEUROPSYCHIATRIC DISORDERS					
FILING DATE:	May 10, 2002	GROUP: 1645					

U.S. PATENT DOCUMENTS

'EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	AA						
	AB	•			· ·		
	AC						
	AD						- · · · · · · · · · · · · · · · · · · ·

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
ВА	, ,			2		
BB						
BC		1		٠, .		

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

,	CA	Bolay, H., et al., "Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model" <i>Nature Medicine</i> , Vol 8, No. 2, February 2002, pp 136-142
	СВ	
•	CC	
	CD	
	CE	
	CF	
	CG	
·	СН	
	CI	
	ಬ	
	СК	

EXAMINER DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. DEPARTMENT (PATENT AND TRAD FORM PTO-1449	EMARK OFFICE	IST OF ART C	Sheet _1_ of _1	
		IST UP ART C	ITED BY APPLICANT) .
ATTY. DOCKET:	17500 (BOT)	OIPE	SERIAL NO.: 10/143,078	4
APPLICANT:	STEPHEN DONOV		TITLE: THERAPEUTIC TREATMENTS FOR NEUROPSYCHIATRIC DISORDERS	, ``
FILING DATE:	May 10, 2002	The Party of Care	GROUP: 1645	

U.S. PATENT DOCUMENTS

"EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME /	CLASS	SUB-CLASS	FILING DATE (if applicable)
· A	A		7			(ii appiioadic)
A	3		/			
A						
A						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
BA	1		1			
BB						
BC		\mathcal{N}				

OTHER ART
(Including Author, Title, Date, Pertinent Pages, etc.)

1/2	H	CA	Cosgrove, G. Rees, et al., Cingulotomy in Psychosurgery, Chpt. 203, pp. 1965-1979; Stereotactic and Functional Neurosurgery, 1998, P. L. Gildenberg, Ed., McGraw-Hill Pub.
V		СВ	Hussain, E.S., et al., A cohort study of psychosurgery cases from a defined population, J. Neurol Neurosurg Psychiatry, 1988 Mar;51(3):345-52
		cc	Kim, C.H., et al., Anterior cingulotomy for refractory obsessive-compulsive diso, Acta Psychiatr Scand. 2003 Apr; 107(4):283-90
		CD	Kim, M.C., et al., Review of long-term results of stereotactic psychosurgery, Neurol Med Chir (Tokyo) 2002 Sep;42(9):365-71
		CE	Sramka, M., et al., Long-term resuls in patients with stereotaxic surgery for psychopathologic disorders, Bratisl Lek Listy 1992 Jul:93(7):364-6 - English Abstract enclosed with Article.
		CF	Yoshimura, D.M., et al., <i>Treatment of Hemifacial Spasm with Botulinum Toxin</i> , Muscle Nerve 1992;15(9): 1045-9
51	J	CG	Yu Y.L., et al., Treatment of idiopathic hemifacial spasm with botulinum toxin, Acta Neurol Scand 1992;85(1):55-57
1.7.2		СН	
		CI	
		3	
		СК	

EXAMINER DATE CONSIDERED *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw life through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

BEST AVAILABLE COPY

U.S. DEPARTMENT OF COMMERC	-
PATENT AND TRADEMARK OFFI	(
FORM PTOLIMO	



Sheet __1__ of __4_

ATTY. DOCKET:	17500 (BOT)	SERIAL NO.: 10/143,078	
APPLICANT:	STEPHEN DONOVAN	TITLE: THERAPEUTIC TREATMEN NEUROPSYCHIATRIC DISORDERS	TS FOR RECEIVE
FILING DATE:	May 10, 2002	GROUP: 1614/645	JUL 3 1 2002
		DATENT DOGUMENTO	Trough

U.S. PATENT DOCUMENTS

TECH CENTER 1600/29

'EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
150	AA	5,989,545	11/23/99	Foster, et al.			(W applicable)
4	AB	6,306,403 B1	10/23/01	Denovan	Vical	se 1) .	
	AC	6,306,423 B1	10/23/01	Donovan, et al.	A		
	AD	•			- V		

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
BA						(Journe)
ВВ						
ВС						

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

	CA	(manager and parties, returned to ages, etc.)
6	CA	Bejjani, B. et al., Bilateral subthalamic stimulation for Parkinson's disease by using three-dimensional stereotactic magnetic resonance imaging and electrophysiological guidance, J. Neurosurg 92:615-625, April 2000
	ÇB	Bellezza, D., et al., Stereotactic Interstitial Brachytherapy, Text book of stereotactic and functional neurosurgery, McGraw-Hill, 1998, Chp. 66, pgs. 577-580
	СС	Bigalke, H., et al., Tetanus Toxin and botulinum a toxin inhibit release and uptake of various transmitters, as studied with particulate preparations from rat brain and spinal cord, Naunyn-Schmiedeberg's Arch Pharmacol (1981) 316:244-251
	CD	Bigalke, H., et al., Botulinum A neurotoxin inhibits non-cholinergic synaptic transmission in mouse spinal cord neurons in culture, Brain Research, 360 (1985) 318-324
	CE	Brem, H., et al., The safety of interstitial chemotherapy with BCNU-loaded polymer follwed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial, J. of Neuro-Oncology 26:111-123, 1995
	CF	Brem, H., et al., Placebo-controlled trial of saety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas, The Lancet, Vol. 345, April 22, 1995, pgs. 1008-1012
1	CG	Burr Leiva, Daniel, <i>The neurochemistry of mania: a hypothesis of etiology and a rationale for treatment</i> , Prog. Neuro-Psychopharmacol & Biol. Psychiat. 1990, Vol. 14, pp 423-429

EXAMINER: DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

BEST AVAILABLE COPY

K F 3

U.S. DEPARTMENT OF PATENT AND TRAD FORM PTO-1449	EMARK OFFICE	Sheet _2_SILE Sheet
ATTY. DOCKET:	17500 (BOT)	SERIAL NO.: 10/143,078
APPLICANT:	STEPHEN DONOVAN	TITLE: THERAPEUTIC TREATMENTS FOR 1600/2300
FILING DATE:	May 10, 2002	GROUP: 1614 / 6 PC

	611	T-
VAR	CH	Cereda, E., et al., Medicinal chemistry of muscarinic agonists for the treatment of dementia disorders, Eur J. Drug Metab Pharmacokinet 1994, Jul-Sep; 19(3): 179-83
	СІ	Clarke, P., et al., Innervation of substantia nigra neurons by cholinergic afferents from pedunculopontine nucleus in the rat: neuroanatomical and electrophysiological evidence, Neuroscience Vol. 23, No. 3, pp 1011-1019, 1987
	3	Cummings, J. L., et al., <i>Alzheimer's disease: cognitive and behavioral pharmacotherapy</i> , Connecticut Medicine, Sept 1997, Vol. 61, No. 9, pp. 543-552
	CK	Fung, L.K., et al., Pharmacokinetics of Interstitial Delivery of Carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain, Cancer Research, 58, 672-684, Feb 15, 1998,
	CL	Garcia-Rill, E., et al., <i>Mesopontine neurons in schizophrenia</i> , Neuroscience Vol. 66, No. 2, pp 321-335, 1995
	CM	Gaspar, L.E., et al., <i>Permanent Iodine implants for recurrent malignant gliomas</i> , Int. J. Radiation Onocology Biol. Phys., Vol. 43, No. 5, pp 977-982, 1999
	CN	German, D.C., et al., <i>Mesopontine cholinergic and non-cholinergic neurons in schizophrenia</i> , Neuroscience, Vol. 94, No. 1, pp. 33-38, 1999
·	co	Gonelle-Gispert, C., et al., SNAP-25a and -25b isofoms are both expressed in insulin-secreting cells and can function in insulin secretion, Biochem. J. (1999) 339; pp. 159-165
	CP	Habermann, E., et al., <i>Tetanus toxin and botulinum A and C neurotoxins inhibit noradrenaline release from cultured mouse brain</i> , J. Neurochemistry, 1988, pp. 522-527
	83	Habermann, E., I-Labeled Neurotoxin from Clostridium botulinum A: preparation, binding to synaptosomes and ascent to the spinal cord, Naunyn-Schmiedeberg's Arch. Pharmacol. 281, 47-56 (1974)
	CR	Habermann, E., Inhibition by tetanus and botulinum A toxin of the release of [³ H]noradrenaline and [³ H]GABA from rat brain homogenate, Experientia 44 (1988) pp 224-226
	CS	Hamson's Principles of Internal Medicine, 1988, 14th Edition, McGraw-Hill , Table 365-8
	СТ	Jankovic, J., et al., <i>Therapy with Botulinum Toxin</i> , Marcel Dekker, Inc. 1994, pg. 150.
/	CU	Jankovic, J., et al., Therapy with Botulinum Toxin, Marcel Dekker, Inc. 1994, pg. 5.
9	CV	Levy, M.L., et al., Neuropsychiatric Symptons and Cholinergic Therapy for Alzheimer's Disease,, Gerontology, 1999;45(suppl 1) 15-22

EXAMINER DATE CONSIDERED *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in *EXAMINER: Initial if reference considered, whether or not chauton is in communication to applicant.

Conformance and not considered. Include copy of this formation to applicant.

AVAILABLE COPY

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE FORM PTO-1449



Shepper CEIVED

IST OF STIT CITED BY APPLICANT

JUL 3 1 2002

ATTY. DOCKET:	17500 (BOT)	SERIAL NO.: 10/143,078 TECH CENTED 1600/2000
APPLICANT:	STEPHEN DONOVAN	TITLE: THERAPEUTIC TREATMENTS FOR NEUROPSYCHIATRIC DISORDERS
FILING DATE:	May 10, 2002	GROUP: 1614 1645

		and or has	
VE	50 1	CW	Marjama-Lyons, J., et al., <i>Tremor-Predominant Parkinson's Disease</i> , Drugs & Aging 2000 Apr; 16(4); 273-278
		CX	Marchese Ragona, R., et al. <i>Management of Parotid Sialocele with Botulinum Toxin</i> , The Laryngoscope 109, Aug 1999, pp. 1344-1346
	1	CY	Meltzer, H., et al., The dopamine hypothesis of schizophrenia: a review,
	1 1		Schizophrenia Bulletin, Vol. 2, No. 1, 1976, pp. 19-76
		CZ	Moyer, E., et al., Botulinum Toxin Type B: Experimental and Clincal Experience,
			Therapy with Botulinum Toxin (1994), Chp. 6, pp71-85
		ÇAA	Movement Disorders, Vol. 10, No. 3, 1995:376
		CBB	Naumann, M., et al., Botulinum toxin type a in the treatment of focal, axillary and
			palmar hyperhidrosis and other hyperhidrotic conditions, European Journal of Neurology 1999, 6 (suppl 4) S111-S115
		CCC	Nowinski, W.L., et al., Computer-Aided stereotactic functional neurosurgery
1)			enhanced by the use of the multiple brain atlas database, IEEE Transactions on
1 1	1		Medical Imaging, Vol. 19, No. 1, Jan 2000, pp. 62-69.
		CDD	Pahapill, P., et al., Tremor arrest with thalamic microinjections of muscimol in
1			patients with essential tremor, Ann Neurol 1999;46:249-252
		CEE	Pearce, L.B., et al., Pharmacologic characterization of botulinum toxin for basic
			science and medicine, Toxicon 1997;35(9):1373-412
		CFF	Sanchez-Prieto, J., et al., Botulinum toxin A blocks glutamate exocytosis from
1			guinea-pig cerebral cortical synaptosomes, Eur J. Biochem 1987 Jun; 165(3):675-
			81
	1	CGG	Sarter, M., et al., Basal forebrain afferent projections modulating cortical
	\		acetylcholine, attention, and implications for neuropsychiatric disorders, ANN NY Acad Sci 1999; 877:368-82
	1	СНН	Schantz, E.J., et al., Properties and use of botulinum toxin and other microbial
	1 1		neurotoxins in medicine, Microbiological Reviews Mar 1992; Vol. 56, No 1; p. 80-99.
		CII	Scharfen, C.O., et al., High activity iodine-125 interstitial implant for gliomas, Int. J.
			Radiation Oncology Biol. Phys., Vol. 24, 1992; pp. 583-591
		cu	Singh, B., Critical aspects of bacterial protein toxins, Chapter 4, Natural Toxins II,
	\perp		Plenum Press (1996) pp. 63-84
	1/10	CKK	Sloop, R., et al., Reconstituted botulinum toxin type A does not lose potentcy in
`	\mathcal{Y}	ı	humans if it is refrozen or refrigerated for 2 weeks before use. Neurology
	V	[1997,48:249-253

EXAMINER DATE CONSIDERED 3 2004

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

7/04

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE FÖRM PTO-1449



SheRECENVED

SLIST OF AST CITED BY APPLICANT

JUL 3 1 2002

ATTY. DOCKET:	17500 (BOT) TA TRADE	SERIAL NO.: 10/143,078 TECH CENTER 1600/2900
APPLICANT:	STEPHEN DONOVAN	TITLE: THERAPEUTIC TREATMENTS FOR NEUROPSYCHIATRIC DISORDERS
FILING DATE:	May 10, 2002	GROUP: 1614 64

180		Tandon, R., et al., <i>The cholinergic system in schizophrenia reconsidered:</i> anticholinergic modulation of sleep and symptom profiles, Neuropsychopharmacology 1999, Vol. 21, No. S6 pp. S189-S202	
V	CMM	Teipel, S.J., et al., <i>In Vivo neuroreceptor imaging and applications for alzheimer's disease</i> , Drug News Perspect 12(6) July 1999, pp. 341-350	
		White, K.E., et al., Schizophrenia and Alzheimer's Disease: clinical and pathophysiologic analogies, Comprehensive Psychiatry, Vol. 37, No. 3 (May/June) 1996, pp 188-195	
	coo	Weigand, H., et al., <i>I-Labelled Botulinum A Neurotoxin: pharmacokinetics in cats after intramuscular injection</i> , Naunyn-Schmiedeberg's Arc. Pharmacol. 292, 161-165 (1976).	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw Une through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.